Multimodal radiomics fusion for predicting postoperative recurrence in NSCLC patients.

purposePostoperative recurrence in non-small cell lung cancer (NSCLC) affects up to 55% of patients, underscoring limits of TNM staging. We assessed multimodal radiomics—positron emission tomography (PET), computed tomography (CT), and clinicopathological (CP) data—for personalized recurrence prediction.

methodsData from 131 NSCLC patients with PET/CT imaging and CP variables were analysed. Radiomics features were extracted using PyRadiomics (1,316 PET and 1,409 CT features per tumor), with robustness testing and selection yielding 20 CT, 20 PET, and 23 CP variables. Prediction models were trained using Logistic Regression (L1, L2, Elastic Net), Random Forest, Gradient Boosting, XGBoost, and CatBoost. Nested cross-validation with SMOTE addressed class imbalance. Fusion strategies included early (feature concatenation), intermediate (stacked ensembles), and late (weighted averaging) fusion.

resultsAmong single modalities, CT with Elastic Net achieved the highest cross-validated AUC (0.679, 95% CI: 0.57–0.79). Fusion improved performance: PET + CT + Clinical late fusion with Elastic Net achieved the best cross-validated AUC (0.811, 95% CI: 0.69–0.91). Out-of-fold ROC curves confirmed stronger discrimination for the fusion model (AUC = 0.836 vs. 0.741 for CT). Fusion also showed better calibration, higher net clinical benefit (decision-curve analysis), and clearer survival stratification (Kaplan–Meier).

conclusionIntegrating PET, CT, and CP data—particularly via late fusion with Elastic Net—enhances discrimination beyond single-modality models and supports more consistent risk stratification. These findings suggest practical potential for informing postoperative surveillance and adjuvant therapy decisions, encouraging a shift beyond TNM alone toward interpretable multimodal frameworks. External validation in larger, multicenter cohorts is warranted.